Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001209191-23-020071
Filing Date
2023-03-20
Accepted
2023-03-20 17:19:05
Documents
2
Period of Report
2023-03-08

Document Format Files

Seq Description Document Type Size
1 FORM 3 SUBMISSION doc3.html 3  
1 FORM 3 SUBMISSION doc3.xml 3 4255
2 POA DOCUMENT poa.txt EX-24 1773
  Complete submission text file 0001209191-23-020071.txt   7384
Mailing Address 2525 WEST END AVENUE SUITE 950 NASHVILLE TN 37203
Business Address 2525 WEST END AVENUE SUITE 950 NASHVILLE, TN 37203 615-255-0068
CUMBERLAND PHARMACEUTICALS INC (Issuer) CIK: 0001087294 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address 1600 WEST END AVENUE SUITE 1300 NASHVILLE TN 37203
Business Address
Bitterman Chris T. (Reporting) CIK: 0001969681 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-33637 | Film No.: 23747150